These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 533888)
21. 9,11-epoxyiminoprosta-5,13-dienoic acid is a thromboxane A2 antagonist in human platelets. Fitzpatrick FA; Bundy GL; Gorman RR; Honohan T Nature; 1978 Oct; 275(5682):764-6. PubMed ID: 703845 [No Abstract] [Full Text] [Related]
22. Characterization of thromboxane receptors in human platelets. Jones RL; Wilson NH; Armstrong RA Adv Exp Med Biol; 1985; 192():67-81. PubMed ID: 3010674 [No Abstract] [Full Text] [Related]
23. Agonist-induced phosphorylation of human platelet TXA2/PGH2 receptors. Okwu AK; Mais DE; Halushka PV Biochim Biophys Acta; 1994 Mar; 1221(1):83-8. PubMed ID: 8130280 [TBL] [Abstract][Full Text] [Related]
24. Thromboxane synthetase inhibitors as pharmacological tools: differential biochemical and biological effects on platelet suspensions. Needleman P; Bryan B; Wyche A; Bronson SD; Eakins K; Ferrendelli JA; Minkes M Prostaglandins; 1977 Nov; 14(5):897-907. PubMed ID: 594391 [TBL] [Abstract][Full Text] [Related]
25. Binding of thromboxane A2/prostaglandin H2 agonists to human platelets. Halushka PV; Kochel PJ; Mais DE Br J Pharmacol; 1987 May; 91(1):223-7. PubMed ID: 3594077 [TBL] [Abstract][Full Text] [Related]
26. 2-(6-carboxyhexyl)cyclopentanone hexylhydrazone: a potent inhibitor of the blood platelet cyclo-oxygenase. Le Breton GC; Hung SC; Ghali NI; Venton DL Prostaglandins; 1984 Apr; 27(4):543-51. PubMed ID: 6427851 [TBL] [Abstract][Full Text] [Related]
27. Ligand binding to thromboxane receptors on human platelets: correlation with biological activity. Armstrong RA; Jones RL; Wilson NH Br J Pharmacol; 1983 Aug; 79(4):953-64. PubMed ID: 6317122 [TBL] [Abstract][Full Text] [Related]
28. 13-Azaprostanoic acid: a specific antagonist of the human blood platelet thromboxane/endoperoxide receptor. Le Breton GC; Venton DL; Enke SE; Halushka PV Proc Natl Acad Sci U S A; 1979 Aug; 76(8):4097-101. PubMed ID: 291066 [TBL] [Abstract][Full Text] [Related]
29. Inhibition of collagen-induced platelet activation by 5'-p-fluorosulfonylbenzoyl adenosine: evidence for an adenosine diphosphate requirement and synergistic influence of prostaglandin endoperoxides. Colman RW; Figures WR; Scearce LM; Strimpler AM; Zhou FX; Rao AK Blood; 1986 Aug; 68(2):565-70. PubMed ID: 3730618 [TBL] [Abstract][Full Text] [Related]
30. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets. Vezza R; Mezzasoma AM; Venditti G; Gresele P Thromb Haemost; 2002 Jan; 87(1):114-21. PubMed ID: 11848439 [TBL] [Abstract][Full Text] [Related]
32. SIN-1, the main metabolite of molsidomine, inhibits prostaglandin endoperoxide analogue- and arachidonic acid-induced platelet aggregation as well as platelet thromboxane A2 formation. Block HU; Förster W; Heinroth I Arzneimittelforschung; 1982; 32(3):189-94. PubMed ID: 6896278 [TBL] [Abstract][Full Text] [Related]
33. Desensitisation of human platelets against stimulation by thromboxane mimics--reduction in receptor capacity and loss of functional response. Thierauch KH; Gabriel D; Prior G; Schillinger E Biomed Biochim Acta; 1988; 47(10-11):S75-8. PubMed ID: 2470362 [TBL] [Abstract][Full Text] [Related]
34. The cleavage of plasmenylethanolamine by phospholipase A2 appears to be mediated by the low affinity binding site of the TxA2/PGH2 receptor in U46619-stimulated human platelets. Turini ME; Holub BJ Biochim Biophys Acta; 1994 Jun; 1213(1):21-6. PubMed ID: 8011675 [TBL] [Abstract][Full Text] [Related]
35. The effects of amrinone on human platelet aggregation: evidence that amrinone does not act through a cyclic nucleotide mechanism in platelet rich plasma. Lippton HL; Horwitz PM; McNamara DB; Ignarro LJ; Landry AZ; Hyman AL; Kadowitz PJ Prostaglandins Leukot Med; 1985 May; 18(2):193-204. PubMed ID: 3925461 [TBL] [Abstract][Full Text] [Related]
37. Effect of thromboxane A2 synthetase inhibition, singly and combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on inositol phospholipid turnover and on 5-HT release by washed human platelets. de Chaffoy de Courcelles D; De Clerck F Eur J Pharmacol; 1990 Mar; 188(2-3):161-9. PubMed ID: 2318257 [TBL] [Abstract][Full Text] [Related]
38. Distinct platelet thromboxane A2/prostaglandin H2 receptor subtypes. A radioligand binding study of human platelets. Dorn GW J Clin Invest; 1989 Dec; 84(6):1883-91. PubMed ID: 2531760 [TBL] [Abstract][Full Text] [Related]
39. Binding of a thromboxane A2/prostaglandin H2 receptor antagonist to washed human platelets. Mais DE; Burch RM; Saussy DL; Kochel PJ; Halushka PV J Pharmacol Exp Ther; 1985 Dec; 235(3):729-34. PubMed ID: 3001275 [TBL] [Abstract][Full Text] [Related]
40. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin. Bertele V; De Gaetano G Eur J Pharmacol; 1982 Dec; 85(3-4):331-3. PubMed ID: 6295787 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]